Asian Journal of Biomedical and Pharmaceutical Sciences

Reach Us +1 (202) 780-3397

Opinion Article - Asian Journal of Biomedical and Pharmaceutical Sciences (2024) Volume 14, Issue 104

Drug reaction variations based on gender

Guowen Wu *

Department of Pharmacy, Wenzhou Medical University, China

*Corresponding Author:

Department of Pharmacy
Wenzhou Medical University
China
E-mail: Wu@Guowen.cn

Received:08-Mar-2024, Manuscript No. AABPS-24-131605; Editor assigned:09-Mar-2024, PreQC No. AABPS-24-131605 (PQ); Reviewed:23-Mar-2024, QC No. AABPS-24-131605; Revised:28-Mar-2024, Manuscript No. AABPS-24-131605 (R); Published:04-Apr-2024, DOI:10.35841/ 14.104.223

Citation: Wu G. Drug reaction variations based on gender. Asian J Biomed Pharm Sci. 2024;14(104):223

Introduction

The field of medicine has long recognized that individuals may react differently to the same medication. While factors such as age, weight, and genetic makeup play crucial roles in these variations, gender also emerges as a significant determinant. Understanding how drugs affect males and females differently is pivotal for optimizing treatment outcomes and ensuring patient safety. This article explores the nuanced differences in drug reactions based on gender and the implications for clinical practice. Biological dissimilarities between males and females influence how drugs are absorbed, distributed, metabolized, and excreted in the body [1, 2].

Hormonal disparities, variances in body composition, and variances in enzyme activity contribute to these differences. For instance, women tend to have a higher proportion of body fat and lower water content than men, which can impact the distribution of lipophilic drugs. Additionally, variances in liver enzyme activity, such as cytochrome P450 enzymes, can lead to variations in drug metabolism between genders. Pharmacokinetics refers to how drugs move through the body, including processes like absorption, distribution, metabolism, and excretion. Gender-based differences in these processes can significantly affect drug concentrations and efficacy [3, 4].

Research suggests that women may generally metabolize drugs more slowly than men, leading to higher drug concentrations and increased susceptibility to adverse effects. Conversely, some drugs may be metabolized more rapidly in women, requiring higher doses for therapeutic efficacy. Pharmacodynamics involves how drugs exert their effects on the body. Gender disparities in receptor sensitivity, hormone levels, and neurotransmitter activity can influence drug responses. For example, studies have shown that women tend to have higher opioid receptor density and may therefore require lower doses of opioids for pain management compared to men [5, 6].

Similarly, variations in hormone levels throughout the menstrual cycle can impact drug responses, particularly in medications targeting the central nervous system. Understanding gender-specific differences in drug reactions is vital for tailoring treatment strategies and optimizing therapeutic outcomes. Healthcare providers should consider gender as a crucial factor when prescribing medications and adjusting dosages. Moreover, clinical trials should strive to include diverse participant populations to elucidate gender-specific responses to drugs accurately [7, 8].

Despite growing recognition of gender-based differences in drug reactions, several challenges persist in translating this knowledge into clinical practice. Limited representation of women in clinical trials, inadequate reporting of sex-specific data, and a lack of awareness among healthcare professionals remain significant barriers. Moving forward, initiatives aimed at promoting gender-inclusive research practices and enhancing medical education on this topic are essential for bridging these gaps [9, 10].

Conclusion

Variations in drug reactions based on gender underscore the importance of personalized medicine approaches in healthcare. By recognizing and addressing these differences, healthcare providers can improve treatment efficacy, minimize adverse effects, and ultimately enhance patient outcomes. Continued research, education, and advocacy efforts are crucial for advancing gender-inclusive healthcare and ensuring equitable access to safe and effective medications for all.

References

  1. McGowan ML, Fishman JR, Lambrix MAPersonal genomics and individual identities: motivations and moral imperatives of early users.New Genet Soc. 2010;29(3):261–290

    2. Indexed at, Google Scholar, Cross Ref

  2. Laestadius LI, Rich JR, Auer PL. All your data (effectively) belong to us: data practices among direct-to-consumer genetic testing firms.. Genet Med. 2017;19(5):513–520.

    3. Indexed at, Google Scholar

  3. Maharjan G, Khadka P, Siddhi Shilpakar G, et al. Utilization of genetic counseling after direct-to-consumer genetic testing: findings from the Impact of Personal Genomics (PGen) Study.. J Genet Couns. 2017;26(6):1270–1279.

    4. Indexed at, Google Scholar, Cross Ref

  4. Kalokairinou L, Howard HC, Slokenberga S, et al. Legislation of direct-to-consumer genetic testing in Europe: a fragmented regulatory landscape. . J Community Genet. 2018; 9(2):117–132

    5. Indexed at,Google Scholar

  5. Howard HC, Borry P. Is there a doctor in the house? The presence of physicians in the direct-to-consumer genetic testing context.. J Community Genet. 2012;3(2):105–112

    6. Indexed at, Google Scholar, Cross Ref

  6. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.Pediat Infect Dis J. 2008;27(4):302-8.

    7. Indexed at, Google Scholar, Cross Ref

  7. Huizing MT, Giaccone G, Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer.J Clin Oncol. 1997;15(1):317–329.

    8. Indexed at, Google Scholar

  8. Mould DR, Fleming GF, Darcy KM. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.Br J Clin Pharmacol. 2006;62(1):56–70.

    9. Indexed at, Google Scholar, Cross Ref

  9. Jiko M, Yano I, Sato E, et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol. 2007;12(4):284–290.

    10. Indexed at,Google Scholar

  10. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel and neutropenia.. Clin Pharmacol Ther. 2005;77(1):43–53.

    11. Indexed at, Google Scholar, Cross Ref

     

Get the App